未登录

K

Kevin S. Scher

Cedars Sinai Medical Center

H指数:18

被引数:2,197

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Detection of Human Papillomavirus (HPV) in HPV-Associated Oropharyngeal Squamous Cell Carcinoma: A Review of Diagnostic Approach and Its Importance for the Head and Neck Oncologist

人乳头瘤病毒（HPV）在HPV相关口咽鳞状细胞癌中的检测：诊断方法及其对头颈肿瘤科医生重要性的综述

Cancers 2026, Vol. 18, Page 56

IF4.4

2025-12-250

OAAI

Patient perceptions underlying ctDNA molecular surveillance for HPV(+) oropharyngeal squamous cell carcinoma

患者对HPV() 口咽鳞状细胞癌的ctDNA分子监测的潜在认知

IF3.9

2024-09-010

PRE

Antagonizing CD105 and androgen receptor to target stromal-epithelial interactions for clinical benefit

MOLECULAR THERAPY

IF12

2023-01-016

OAAI

Quantitative Nodal Burden and Mortality Across Solid Cancers

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE

IF7.2

2022-03-216

OA

Nodal staging convergence for HPV- and HPV plus oropharyngeal carcinoma

HPV和HPV加口咽癌的淋巴结分期趋同

IF5.1

2021-02-1711

OAAI

The role of concomitant chemoradiotherapy in AJCC 7th edition T1-2N1 oropharyngeal carcinoma in the human papillomavirus era

同步放化疗在人乳头瘤病毒时代AJCC第7版T1-2N1口咽癌中的作用

IF3.9

2020-11-012

PREAI

Predictors of hospital readmission among older adults with cancer

JOURNAL OF GERIATRIC ONCOLOGY

IF2.7

2020-09-0115

OAAI

Survival outcomes with concomitant chemoradiotherapy in older adults with oropharyngeal carcinoma in an era of increasing human papillomavirus (HPV) prevalence

IF3.9

2019-12-015

PREAI

Quantitative lymph node burden as a 'very-high-risk' factor identifying head and neck cancer patients benefiting from postoperative chemoradiation (vol 30, pg 7634, 2019)

ANNALS OF ONCOLOGY

IF65.4

2019-10-013

OAAI

Stage I HPV-positive oropharyngeal cancer: Should all patients receive similar treatments?

I期HPV阳性口咽癌: 所有患者都应该接受类似的治疗吗？

IF5.1

2019-09-1910

OAAI

Stage I HPV-positive Oropharyngeal Cancer: Should All Patients Receive Similar Treatments?

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

IF6.5

2019-09-010

PREAI

Survival Outcomes with Concomitant Chemoradiotherapy in Older Adults with Oropharyngeal Carcinoma in an Era of Increasing Human Papillomavirus (HPV) Prevalence

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

IF6.5

2019-09-010

OAAI

A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer

IF10.8

2019-02-0189

OAAI

Quantitative lymph node burden as a 'very-high-risk' factor identifying head and neck cancer patients benefiting from postoperative chemoradiation

ANNALS OF ONCOLOGY

IF65.4

2019-01-0124

OAAI

HPV-Associated Oropharyngeal Cancer Among Elderly Patients: Dramatically Increased Prevalence and Clinical Implications

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

IF6.5

2018-11-010

PREAI

Human papillomavirus-associated oropharyngeal cancer among patients aged 70 and older: Dramatically increased prevalence and clinical implications

EUROPEAN JOURNAL OF CANCER

IF7.1

2018-11-0130

PREAI

Quantitative Survival Impact of Composite Treatment Delays in Head and Neck Cancer

IF5.1

2018-05-0969

OAAI

Survival Impact of Treatment Interval Delays in Head and Neck Cancer

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

IF6.5

2018-04-010

OAAI

Survival in Asian-Americans With Nasopharyngeal Cancer Undergoing Definitive Radiation Therapy

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

IF6.5

2018-04-011

PREAI

Facility Volume and Survival in Nasopharyngeal Carcinoma

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

IF6.5

2018-02-0135

PREAI